I'm for one, grateful for internet broadband access. It gives you something to do, while your plane is delayed.
Tiger, extremely misleading your previous message, I don't think Bloomberg is referring to the likes of the MAYO clinic or Quest. These biotech companies are most likely startups, having a hard time getting venture funding.
Either way you slice it, clinical trial testing is moving to India, and Russia could be the next big area see some action. This requires shipping frozen specimens through-out the globe, and dry ice doesn't cut it any longer.
As Bostonman stated, we're starting from zero, so there's only one way for us to go, and that's up.
To LongCYRX, Easy just to sell out IMO. We have to start funding those out-sourcing operations. Unless CYRX gets up front payments, we're going to have to dip into our pockets, or have to dilute our company even further.
I doubt 1.2 million will get us far.
If we out-source everything, what are we going to do, research and development?
Mr. Berry probably wants to take his 1.4 million options, and sail off into the sunset.
Personally speaking, I think if we can lock down another Quest, MAYO or TATA,
in the form of Quintiles, Covance or Lab Corp Esoterix, you've become not a Major Force, but a leading force in cold chain transportation. I think we're already becoming a major force.
As I mentioned before, CYRX needs to show growth via numbers, that's our first goal.
I don't think the broad market will play a major roll, but it would certainly help if the markets were acting a lot healthier.
Finally, my flight is boarding.
GLTA
RMS
Market Data 
Markets 
AI
